| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 73036 |
SPDP-Val-Cit-PAB-OH，ADC定制 |
65 |
wyh |
2024-12-19 |
| 73037 |
DOTA-LVT 螯合剂DOTA偶联Lys8-血管收缩素 |
86 |
h |
2024-12-19 |
| 73038 |
cas:2054345-67-2，azido-tris(ethylenoxy)-L-alanine TFA Salt化学性质 |
82 |
zyl |
2024-12-19 |
| 73039 |
cas:68617-64-1，SPDP acid，3-(2-吡啶二硫代)丙酸的合成方法 |
115 |
zyl |
2024-12-19 |
| 73040 |
1,4,7,10-四(羧甲基)-1,4,7,10-四氮杂环十二烷单酰胺偶联葡萄糖 |
81 |
h |
2024-12-19 |
| 73041 |
PEG-P(Asp-Gd-DOTA)Gd‐DOTA偶联聚乙二醇改性聚天冬氨酸 |
86 |
h |
2024-12-19 |
| 73042 |
cas:70539-42-3，EGS Crosslinker，乙二醇-双(琥珀酸N-羟基琥珀酰亚胺酯)的结构式 |
133 |
zyl |
2024-12-19 |
| 73043 |
CXCR4导向的五肽[(68)Ga]喷替沙福(环(-D-Tyr-N-Me-D-Orn(AMB-DOTA)-L-Arg-L-2-Nal-Gly-)) |
111 |
h |
2024-12-19 |
| 73044 |
α-hexadecyl-DOTA α-十六烷基-DOTA |
82 |
h |
2024-12-19 |
| 73045 |
Methyltetrazine-SS-NHS 甲基四唑-双硫键-活性酯的合成方法 |
72 |
zyl |
2024-12-19 |
| 73046 |
DOTA-AgRP-6E |
109 |
h |
2024-12-19 |
| 73047 |
DOTA-morab-003 DOTA偶联单克隆抗体MORAb-003 |
72 |
h |
2024-12-19 |
| 73048 |
DOTA-Bz-folate DOTA-Bz-叶酸 |
88 |
h |
2024-12-19 |
| 73049 |
cas:55750-53-3，6-Maleimidocaproic acid，6-马来酰亚氨基己酸 |
99 |
zyl |
2024-12-19 |
| 73050 |
cas: Fmoc-PEG3-Val-Cit，ADC定制 |
78 |
wyh |
2024-12-19 |
| 73051 |
钆(III)DOTA-DSPE脂质体 |
76 |
h |
2024-12-19 |
| 73052 |
CAS: 870487-08-4，Boc-Val-Cit，叔丁氧羰基-缬氨酰-L-瓜氨酸 |
69 |
WYQ |
2024-12-19 |
| 73053 |
DOTA-Phe-D-Trp-Lys-Thr-OMe DOTA偶联生长抑素四肽类似物 |
99 |
h |
2024-12-19 |
| 73054 |
CAS: 35665-38-4，Fmoc-Gly-Gly-OH，Fmoc-甘氨酰-甘氨酸 |
101 |
WYQ |
2024-12-19 |
| 73055 |
cas:117235-10-6，3-Mercaptopropanyl-N-hydroxysuccinimide ester的结构式 |
101 |
zyl |
2024-12-19 |
| 73056 |
DOTA-PEG(4)-BBN(7-14)-AuNP DOTA-神经介素n功能化NHS活化的PEG-金纳米颗粒 |
70 |
h |
2024-12-19 |
| 73057 |
cas:2226472-28-0，DBCO-PEG4-Val-Cit-PAB-PNP，ADC定制 |
64 |
wyh |
2024-12-19 |
| 73058 |
CAS: 863971-53-3，Fmoc-Val-Cit-PAB-PNP |
81 |
WYQ |
2024-12-19 |
| 73059 |
tris-苄基-DOTA tris-benzyl-DOTA |
101 |
h |
2024-12-19 |
| 73060 |
DOTA-DN(PTX)-BN DOTA-铃蟾肽功能化聚酰胺胺(PAMAM)树状大分子(DN)负载紫杉醇 |
87 |
h |
2024-12-19 |
| 73061 |
NH2-Sar10-COOH，ADC定制 |
72 |
wyh |
2024-12-19 |
| 73062 |
cas:1415328-95-8，NHPI-PEG4-C2-NHS ester |
86 |
zyl |
2024-12-19 |
| 73063 |
Gd-GlyMe-DOTA-全氟辛基甘露糖缀合物(Gadofluorine M) |
122 |
h |
2024-12-19 |
| 73064 |
MC-Val-Cit-PAB-PNP（CAS号：159857-81-5） |
109 |
WYQ |
2024-12-19 |
| 73065 |
Mal-Gly-Gly-L-Phe-N-[(carboxymethoxy)methyl]Glycinamide，ADC定制 |
81 |
wyh |
2024-12-19 |
| 73066 |
L-RNA寡核苷酸的功能化DOTA |
87 |
h |
2024-12-19 |
| 73067 |
MA-PEG4-Glu(t-Bu)-Val-Cit-PAB-PNP，在药物递送系统中具有广泛应用潜力 |
74 |
WYQ |
2024-12-19 |
| 73068 |
cas:1415800-42-8，perfluorophenyl 1-(2,5-dioxo-2H-pyrrol-1(5H)-yl)-3,6,9,12-tetraoxapentadecan-15-oate |
63 |
zyl |
2024-12-19 |
| 73069 |
羟基磺基琥珀酰亚胺DOTA(DOTA-OSSu) |
107 |
h |
2024-12-19 |
| 73070 |
Mal-PEG1-Val-Cit-OH，生物化学和药物研发领域有潜在应用 |
83 |
WYQ |
2024-12-19 |
| 73071 |
cas:1193111-39-5，1-(2,5-dioxopyrrolidin-1-yloxy)-1-oxo-4-(pyridin-2-yldisulfanyl)butane-2-sulfonic acid |
75 |
zyl |
2024-12-19 |
| 73072 |
DOTA-GGG-BN(7-14) |
79 |
h |
2024-12-19 |
| 73073 |
CAS: 108-30-5，Dihydrofuran-2,5-dione（丁二酸酐） |
99 |
WYQ |
2024-12-19 |
| 73074 |
cas:1884578-00-0 Boc-Val-Ala-PAB-PNP |
89 |
zyl |
2024-12-19 |
| 73075 |
DOTA-L22-异硫氰酸荧光素-依沙酸 |
76 |
h |
2024-12-19 |
| 73076 |
cas:2768446-73-5 DBCO-Val-Cit-PAB-MMAE |
71 |
zyl |
2024-12-19 |
| 73077 |
Boc-PEG4-Val-Ala-PAB，ADC定制 |
79 |
wyh |
2024-12-19 |
| 73078 |
CAS: 2504147-59-3，MC (C5)-Val-Cit |
65 |
WYQ |
2024-12-19 |
| 73079 |
CAS: 159857-80-4，MC-Val-Cit-PAB-OH |
80 |
WYQ |
2024-12-19 |
| 73080 |
cas:2055024-65-0 Azido-PEG3-Val-Cit-PAB-OH |
80 |
zyl |
2024-12-19 |
齐岳微信公众号
官方微信
库存查询